Sino Biopharmaceutical Limited reported its results for the six months ended 30 June 2025. The company recorded revenue of RMB17.57 billion, reflecting an increase of 10.7% compared to the same period last year. Profit attributable to owners of the parent from continuing operations was RMB3.39 billion, representing an increase of 140.2% year-on-year. Basic earnings per share from continuing operations were RMB18.82 cents, up 145.7% from the prior-year period. Sales of innovative products reached RMB7.80 billion, an increase of 27.2% from RMB6.13 billion a year earlier, and accounted for 44.4% of total revenue, up from 38.6% previously. The board of directors declared an interim dividend of HK5 cents per share for the six months ended 30 June 2025. The company attributed the increase in profit to growth in revenue, higher dividend income, and fair value gains on investments during the period. Sino Biopharmaceutical's operations cover R&D, production, and sales, with products spanning therapeutic areas such as oncology, liver and metabolic diseases, respiratory, and surgery/analgesia.